1. What are the most common side effects of cablivi ?

The most common cablivi side effects include nosebleeds, gum bleeding, headache, fatigue, and injection site reactions.

2. Are side effects of cablivi dangerous?

Most cablivi side effects are mild, but serious bleeding events can occur in rare cases.

3. Can Cablivi cause internal bleeding?

Yes, internal bleeding is a known risk among side effects of cablivi, especially when combined with blood thinners.

4. Should Cablivi be stopped before surgery?

Yes, physicians may temporarily stop therapy to reduce surgical bleeding risk.

5. Does Cablivi interact with anticoagulants?

Yes, combining anticoagulants increases bleeding-related cablivi side effects.

6. How long do side effects of cablivi last?

Most cablivi side effects resolve after discontinuation of therapy.

trustedpharamguide.com -

Cablivi Side Effects: The Ultimate Clinical Guide for Patients and Healthcare Professionals

February 10, 2026 by Shubhangi Shelke

Introduction Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening hematologic disorder characterized by widespread microvascular thrombosis, severe thrombocytopenia, and organ ischemia. Before the introduction of targeted biologics, mortality rates were significantly high despite plasma exchange therapy. The development of caplacizumab (marketed as Cablivi) marked a breakthrough in the management of aTTP. However, as with …

Darzalex Faspro Mechanism of Action: Advanced Clinical Guide to MOA, FDA Approval, Side Effects & Drug Interactions

February 9, 2026 by Shubhangi Shelke

Introduction Multiple myeloma is a plasma cell malignancy characterized by uncontrolled monoclonal expansion in the bone marrow, leading to anemia, bone lesions, hypercalcemia, renal dysfunction, and immunosuppression. Over the past decade, targeted immunotherapies have dramatically improved outcomes. Among them, understanding the darzalex faspro mechanism of action is essential for appreciating how modern oncology has shifted …

Yuvezzi Eye Drop – A Complete Clinical and Patient Guide

February 5, 2026 by Shubhangi Shelke

Introduction Age-related vision changes affect millions of adults worldwide, and one of the most common conditions is presbyopia. As people age, the natural lens of the eye becomes less flexible, making it harder to focus on nearby objects. Reading small print, checking a smartphone, or working on a laptop may suddenly require reading glasses. Yuvezzi …

Filkri Biosimilar Approval: What It Means for Supportive Oncology Care in 2026 and Clinical Perspectives Beyond Oncology

February 3, 2026 by Shubhangi Shelke

Introduction The healthcare landscape in 2026 continues to evolve rapidly, especially in oncology where innovation in both treatment and supportive care remains critical. Among the major regulatory milestones this year is the Filkri biosimilar Approval, a development that holds significant implications for cancer patients undergoing chemotherapy. Supportive oncology care is no longer considered secondary; it …

Ustekinumab Biosimilar FDA Approval: A Complete Clinical and Regulatory Guide

February 2, 2026 by Shubhangi Shelke

Biologic therapies have revolutionized the treatment of chronic inflammatory diseases over the last two decades. Among these, ustekinumab has stood out as a highly effective monoclonal antibody targeting immune-mediated disorders. With the growing interest in affordability and access, ustekinumab biosimilar FDA approval has become a highly discussed topic in the medical and pharmaceutical community. Understanding …

Aficamten vs Mavacamten: Which Is Better for Hypertrophic Cardiomyopathy?

January 30, 2026 by Shubhangi Shelke

Introduction The treatment landscape for hypertrophic cardiomyopathy (HCM) has dramatically evolved over the past few years. For decades, patients relied primarily on beta-blockers, calcium channel blockers, or invasive procedures like septal myectomy. However, the introduction of cardiac myosin inhibitors revolutionized care. Today, the debate of Aficamten vs Mavacamten is central to discussions among cardiologists, pharmacists, …

Zycubo FDA Approval: A Historic Breakthrough for Menkes Disease Treatment in Pediatric Patients

January 29, 2026 by Shubhangi Shelke

Introduction The approval of novel therapies for rare pediatric diseases represents one of the most critical challenges in modern medicine. Many rare genetic disorders remain underdiagnosed, undertreated, and historically overlooked due to limited commercial incentives and scientific complexity. Against this backdrop, the Zycubo FDA approval stands as a landmark achievement in pediatric rare disease therapy. …

Blincyto Mechanism of Action: A Comprehensive Scientific and Clinical Overview

January 23, 2026 by Shubhangi Shelke

Introduction Immunotherapy has transformed the landscape of cancer treatment, especially in hematologic malignancies where traditional chemotherapy often falls short. One of the most groundbreaking innovations in this space is Blincyto (blinatumomab). The Blincyto mechanism of action represents a paradigm shift from non-specific cytotoxic therapy to precise immune-directed tumor killing. Blincyto is the first FDA-approved bispecific …

Uplizna Mechanism of Action: A Complete Clinical Guide to MOA, Side Effects, FDA Approval & Drug Interactions

January 22, 2026 by Shubhangi Shelke

Introduction The rapid advancement of biologic therapies has transformed the treatment landscape for autoimmune and antibody-mediated diseases. Among these innovations, Uplizna (inebilizumab-cdon) stands out as a targeted monoclonal antibody designed to modify disease progression rather than merely suppress symptoms. Understanding the Uplizna Mechanism of Action is essential for clinicians, pharmacists, researchers, and patients seeking deeper …

Understanding the Rybrevant Lazcluze MOA in First-Line EGFR-Mutated NSCLC

January 21, 2026 by Shubhangi Shelke

1.Introduction: Shifting the Paradigm in Lung Cancer Treatment Non-small cell lung cancer (NSCLC) remains a formidable challenge in oncology, particularly for patients whose tumors harbor activating mutations in the epidermal growth factor receptor (EGFR) gene. For years, EGFR tyrosine kinase inhibitors (TKIs) have served as the cornerstone of first-line therapy, offering significant improvements over traditional …